223 related articles for article (PubMed ID: 16755002)
1. Strain differences in the diabetogenic activity of streptozotocin in mice.
Hayashi K; Kojima R; Ito M
Biol Pharm Bull; 2006 Jun; 29(6):1110-9. PubMed ID: 16755002
[TBL] [Abstract][Full Text] [Related]
2. New model of progressive non-insulin-dependent diabetes mellitus in mice induced by streptozotocin.
Ito M; Kondo Y; Nakatani A; Naruse A
Biol Pharm Bull; 1999 Sep; 22(9):988-9. PubMed ID: 10513628
[TBL] [Abstract][Full Text] [Related]
3. Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide.
Nakamura T; Terajima T; Ogata T; Ueno K; Hashimoto N; Ono K; Yano S
Biol Pharm Bull; 2006 Jun; 29(6):1167-74. PubMed ID: 16755011
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight chitosan prevents the progression of low dose streptozotocin-induced slowly progressive diabetes mellitus in mice.
Kondo Y; Nakatani A; Hayashi K; Ito M
Biol Pharm Bull; 2000 Dec; 23(12):1458-64. PubMed ID: 11145178
[TBL] [Abstract][Full Text] [Related]
5. Characterization of low dose streptozotocin-induced progressive diabetes in mice.
Ito M; Kondo Y; Nakatani A; Hayashi K; Naruse A
Environ Toxicol Pharmacol; 2001 Jan; 9(3):71-78. PubMed ID: 11167151
[TBL] [Abstract][Full Text] [Related]
6. [The production of mouse model of slowly progressive diabetes mellitus and the preventive effect of low molecular weight chitosan on the progression of the diabetes mellitus].
Ito M
Yakugaku Zasshi; 2013; 133(7):773-82. PubMed ID: 23811765
[TBL] [Abstract][Full Text] [Related]
7. Development of an alternative non-obese non-genetic rat model of type 2 diabetes using caffeine and streptozotocin.
Naidoo P; Islam MS
Pharmacol Rep; 2014 Aug; 66(4):585-93. PubMed ID: 24948058
[TBL] [Abstract][Full Text] [Related]
8. Effect of cerebrocrast, a new long-acting compound on blood glucose and insulin levels in rats when administered before and after STZ-induced diabetes mellitus.
Briede J; Stivrina M; Stoldere Dz; Vigante B; Duburs G
Cell Biochem Funct; 2007; 25(6):673-80. PubMed ID: 16986170
[TBL] [Abstract][Full Text] [Related]
9. Nongenetic mouse models of non-insulin-dependent diabetes mellitus.
Luo J; Quan J; Tsai J; Hobensack CK; Sullivan C; Hector R; Reaven GM
Metabolism; 1998 Jun; 47(6):663-8. PubMed ID: 9627363
[TBL] [Abstract][Full Text] [Related]
10. Streptozotocin is equally diabetogenic whether administered to fed or fasted mice.
Chaudhry ZZ; Morris DL; Moss DR; Sims EK; Chiong Y; Kono T; Evans-Molina C
Lab Anim; 2013 Oct; 47(4):257-65. PubMed ID: 23760565
[TBL] [Abstract][Full Text] [Related]
11. Difference in glucose intolerance between C57BL/6J and ICR strain mice with streptozotocin/nicotinamide-induced diabetes.
Shimizu R; Sakazaki F; Okuno T; Nakamuro K; Ueno H
Biomed Res; 2012 Feb; 33(1):63-6. PubMed ID: 22361889
[TBL] [Abstract][Full Text] [Related]
12. Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass.
Meier JJ; Ueberberg S; Korbas S; Schneider S
Am J Physiol Endocrinol Metab; 2011 Apr; 300(4):E717-23. PubMed ID: 21285404
[TBL] [Abstract][Full Text] [Related]
13. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal co-administration of thymosin alpha-1 ameliorates streptozotocin-induced pancreatic lesions and diabetes in C57BL/6 mice.
Qiu L; Zhang C; Zhang J; Liang J; Liu J; Ji C; Yang JY
Int J Mol Med; 2009 May; 23(5):597-602. PubMed ID: 19360317
[TBL] [Abstract][Full Text] [Related]
15. A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans.
Nath S; Ghosh SK; Choudhury Y
J Pharmacol Toxicol Methods; 2017; 84():20-30. PubMed ID: 27773844
[TBL] [Abstract][Full Text] [Related]
16. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
[TBL] [Abstract][Full Text] [Related]
17. Investigation of insulin resistance in the popularly used four rat models of type-2 diabetes.
Chao PC; Li Y; Chang CH; Shieh JP; Cheng JT; Cheng KC
Biomed Pharmacother; 2018 May; 101():155-161. PubMed ID: 29486333
[TBL] [Abstract][Full Text] [Related]
18. Comparison of single high-dose streptozotocin with partial pancreatectomy combined with low-dose streptozotocin for diabetes induction in rhesus monkeys.
Jin X; Zeng L; He S; Chen Y; Tian B; Mai G; Yang G; Wei L; Zhang Y; Li H; Wang L; Qiao C; Cheng J; Lu Y
Exp Biol Med (Maywood); 2010 Jul; 235(7):877-85. PubMed ID: 20558842
[TBL] [Abstract][Full Text] [Related]
19. Safe induction of diabetes by high-dose streptozotocin in pigs.
Hara H; Lin YJ; Zhu X; Tai HC; Ezzelarab M; Balamurugan AN; Bottino R; Houser SL; Cooper DK
Pancreas; 2008 Jan; 36(1):31-8. PubMed ID: 18192878
[TBL] [Abstract][Full Text] [Related]
20. Long-term changes in the diabetic state induced by different doses of streptozotocin in rats.
Tancrède G; Rousseau-Migneron S; Nadeau A
Br J Exp Pathol; 1983 Apr; 64(2):117-23. PubMed ID: 6221747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
